argenx SE

ARGX • Biotechnology

$825.61

— 0.00 (0.00%)

EarningsLatest report: Dec 31, 2025

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$54.65B

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Stable or improving margins · 31.1%Positive revenue growth · 62.4%Positive free cash flow · 13.77Manageable debt level · 0.01Healthy liquidity · 5.23

Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$825.61

Change0.00%

Shares Out66.20M

Market Cap$54.65B

Enterprise Value$50.26B

52W Range510.06 - 934.62

Beta-0.03

P/E23.48

P/S8.68

P/B7.46

P/FCF86.99

EV/Sales7.98

Price$825.61

Change0.00%

Shares Out66.20M

Market Cap$54.65B

Enterprise Value$50.26B

52W Range510.06 - 934.62

Beta-0.03

P/E23.48

P/S8.68

P/B7.46

P/FCF86.99

EV/Sales7.98

EV/EBITDA37.83

EV/FCF80.00

Earnings Yield4.26%

FCF Yield1.15%

Dividend Yield0.00%

Gross Margin89.15%

Oper. Margin25.39%

Profit Margin31.11%

Debt/Eq0.01

Current Ratio5.23

Quick Ratio4.87

Target$1,138.60

Target Upside37.91%

Target Median$1,140.00

Target Range823.00 - 1400.00

Volume714.48K

Avg Volume327.48K

EPS Surprise-0.37

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

90/100

Financial Strength

Debt, cash, stability

95/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

25/100

Why this score▼

Stable or improving margins · 31.1%Positive revenue growth · 62.4%Positive free cash flow · 13.77Manageable debt level · 0.01Healthy liquidity · 5.23Expensive earnings multiple · 39.9

Analyst view

Analyst sentiment and price target

ARGX

Analyst sentiment

Based on 36 analyst votes · 2026-10-20

94/100

Bullish

Hold

Bearish

Price Target

2026-06-24

Low

$940.00

Mean

$1136.83

Median

$1152.50

High

$1291.00

Company Overview

IPO: 5/18/2017

Industry: Biotechnology

P/B i: 7.46

Debt / Equity i: 0.01

Operating Margin: 25.39%

Net Margin: 31.11%

ROE i: -

ROIC: -

Financial Health

Score19 / 20

Debt / Equity: 0.01

Current Ratio: 5.23

Quick Ratio: 4.87

Status: Strong

🧾

No insider activity

No recent insider transactions available.

About the Company

argenx SE

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

Source - link

Peers

A ALC ALNY BDX CAH EW HLN IDXX REGN VEEV

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.

GlobeNewsWire

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.

Business Wire

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

Zacks Investment Research

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.

Zacks Investment Research

argenx: The Sjögren's Selloff Looks Overdone

argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. VYVGART franchise remains robust, driving strong cash generation and funding pipeline advancements, despite setbacks in expanding indications. At ~8x annualized sales, ARGX trades at a discount to peers like Vertex, supporting a reiterated 'Buy' rating based on growth prospects.

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	6.27	5.9	-0.37
2025-10-30	4.37	5.18	0.81
2025-05-08	0.98	2.58	1.6
2024-10-31	0.1	1.39	1.29
2024-05-09	-0.71	-1.04	-0.33
2023-10-31	-1.48	-1.25	0.23
2023-05-04	-2.34	-0.52	1.82
2022-10-27	-3.5	-4.26	-0.76
2021-10-28	-4.48	-4.4	0.08
2021-05-14	-3.14	-0.81	2.33
2020-10-22	-2.39	-3.39	-1
2020-05-14	-1.88	-2.06	-0.18